Management and Outcome of Primary CNS Lymphoma in the Modern Era
Neurol 94:e1027-e1039, Houillier, C., et al, 2020
Neurologic IgG4-Related Disease
Neurohospitalist 9:118-119, Topiwala, K.,et al, 2019
Antibody-Mediated Encephalitis
NEJM 378:840-851, Dalmau, J.,et al, 2018
Overview of IgG4-related Disease
UptoDate, July, Moutsopoulos,H.,et al, 2017
Rituximab as Treatment for anti-MuSK myasthenia gravis
Neurol 89:1069-1077, Hehir, M.K.,et al, 2017
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era
Am J Transplant 13:1512-1522, Evens, A.M.,et al, 2013
Long-lasting Treatment Effect of Rituximab in MuSK Myasthenia
Neurol 78:189-193, Diaz-Manera,J.,et al, 2012
Rituximab Monotherapy for Patients With Recurrent Primary CNS Lymphoma
Neurol 76:929-930, Batchelor,T.T.,et al, 2011
Primary Central Nervous System Post-Transplantation Lymphoproliferative Disorder
CANCER 16:863-870, Cavaliere, R.,et al, 2010
B-Cell Depletion with Rituximab in Relapsing-Remitting Multiple Sclerosis
NEJM 358:676-688, Hauser,S.L.,et al, 2008
Progressive Multifocal Leukoencephalopathy After Rituximab in a Case of Non-Hodgkin Lymphoma
Neurol 69:704-706, Kranick,S.M.,et al, 2007
Salvage Therapy for Primary CNS Lymphoma with a Combination of Rituximab and Temozolomide
Neurol 63:901-903, Enting,R.H.,et al, 2004